Madrigal Pharmaceuticals, Inc. Banner Image

Madrigal Pharmaceuticals, Inc.

  • Ticker MDGL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Madrigal Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Conshohocken, Pennsylvania
Madrigal Pharmaceuticals, Inc. (Nasdaq Global Select: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-inMore- class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.
Madrigal Pharmaceuticals, Inc.

Most Recent Annual Report

Madrigal Pharmaceuticals, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports